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Objective: Transbronchial needle aspiration is a useful diagnostic procedure in sar-
coidosis, but widely variable yields are reported. This study determined the diagnostic
contribution of standard transbronchial needle aspiration in a large series of patients
with sarcoidosis and evaluated predictor variables that might influence its results.
Methods: Sixty-one consecutive patients with suspected sarcoidosis in a 2-year period
were prospectively enrolled and underwent standard transbronchial needle aspiration
with a 19-gauge needle. The following predictor variables were recorded for each
patient: age; sex; sarcoidosis stage; operator; size, location, and number of sampled
lymph nodes; number of needle passes per sampled node; and adequacy of both
histologic and cytologic transbronchial needle aspiration specimens.
Results: Sarcoidosis was diagnosed in 53 patients. Lymph node aspiration biopsy was
successfully achieved in 50 of 53 cases (94%). Nonnecrotizing epithelioid granulo-
mas were observed in 42 of 53 patients (79%), with similar results for stage I (27/
33, 82%) and stage II (15/20, 75%) disease. Sampling of two lymph node stations
was the only variable significantly associated with a likelihood of a sarcoidosis-
positive aspirate or biopsy sample in both univariate (odds ratio 0.15, 95% confidence
interval 0.02–0.79) and multivariate (odds ratio 0.12, 95% confidence interval 0.02–
0.70) analyses.
Conclusion: Standard transbronchial needle aspiration allows successful lymph node
sampling in nearly all patients with sarcoidosis and is associated with high diagnostic
yield regardless of disease stage.Whenever possible, sampling of more than one nodal
station is advised to increase diagnostic yield. Mediastinoscopy should be reserved for
patients with negative transbronchial needle aspiration findings.
M
ediastinoscopy is associated with the best diagnostic yield in the pathologic
confirmation of sarcoidosis with mediastinal involvement (stages I and II of
the disease).1 Nonetheless, risk–benefit and cost–benefit analyses,2 as well
as the development of transbronchial needle aspiration (TBNA), a minimally invasive
bronchoscopic procedure that allows aspiration from the mediastinum, have markedly
decreased the use of mediastinoscopy in this setting.
TBNA, developed for use with flexible bronchoscopy in the 1980s, was mainly
used for the diagnosis and staging of lung cancer.3 In this specific setting, several stud-
ies evaluated a number of factors to explain the differences seen among the reported
diagnostic yields of the procedure and found several predictors of a positive TBNA
aspirate, such as high prevalence of lymph node metastasis in the study population,4,5
increasing lymph node size,6,7 right paratracheal and subcarinal locations,6,8 use of
a histology needle,9 use of rapid on-site cytopathologic examination (ROSE),7,10
and small cell carcinoma histologic type.6,7
No such studies are available for use of TBNA in the setting of sarcoidosis. Fur-
thermore, the few studies that have specifically addressed the diagnostic value of
TBNA in sarcoidosis, predominantly retrospective, have reported highly variable
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yields.11-16 The likelihood of a diagnostic TBNA was much
higher in patients with stage I than stage II disease in most
studies,12-15 and some authors have hypothesized that stage
I lymph nodes could have a higher density of granulomas.11
We performed a prospective study to determine more pre-
cisely the diagnostic contribution of standard TBNA in cases




This study was approved by the ethics committee of the Azienda
USL di Bologna, and all study participants provided written, in-
formed consent. Consecutive patients referred to the Thoracic En-
doscopy Unit of Maggiore Hospital (Bologna, Italy) for pathologic
confirmation of suspected sarcoidosis with hilar or mediastinal in-
volvement (stage I and II) between January 1, 2004, and December
31, 2005, were prospectively studied.
Because presentations of sarcoidosis vary enormously, the
expectation of the disease was based on a variable combination of
clinical and imaging findings. Clinically, nonspecific constitutional
manifestations (fever, fatigue, malaise, weight loss), respiratory
symptoms (especially cough and dyspnea), erythema nodosum, ar-
thralgias, palpable peripheral enlarged lymph nodes, and findings
related to specific organ involvement (eg, uveitis, skin lesions)
were carefully evaluated. Imaging studies included both chest radi-
ography and contrast-enhanced computed tomography (CT) in each
case, but radiographic staging of the disease was based on the post-
eroanterior chest radiograph, as universally accepted.17
After CT scan, each patient underwent bronchoscopy with
TBNA, transbronchial lung biopsy (TBLB), and bronchoalveolar la-
vage. The following variables were recorded for each patient: age;
sex; sarcoidosis stage; operator performing the procedure; size, loca-
tion, and number of sampled lymph nodes; number of needle passes
for each sampled lymph node; and adequacy of cytologic and histo-
logic TBNA specimens.
Patients with inconclusive results of bronchoscopic procedures
underwent mediastinoscopy. For those who refused surgery, accu-
rate clinical and radiologic follow-up were carried out. Patients
ultimately found not to have sarcoidosis were excluded from the
analysis.
Two well-trained bronchoscopists (MP and RT) performed
TBNAs during flexible bronchoscopy with a 19-gauge histology
needle (MW-319; ConMed Endoscopic Technologies, Billerica,
Mass) according to a previously described technique.8,18 Before
any other sampling procedures, one to three needle passes were per-
formed on one or two stations of the American Thoracic Society
classification scheme19; in most patients who had a single node
station punctured, three needle passes were performed. Only lymph838 The Journal of Thoracic and Cardiovascular Surgery c Aprnodes with a short axis greater than 1 cm at CT scan were selected
for aspiration. The location and the number of stations to be sampled
in the individual patient were left to the discretion of each operator,
but preference was given to enlarged nodes in the right paratracheal
and subcarinal stations, because TBNA in those areas was consis-
tently associated with the highest yield in the settings of both
neoplastic and granulomatous disorders.6,8,15,16,20,21 All TBNA
specimens from a single site were pooled as a combined specimen.
Handling of Aspirates and Pathologic Categorization
of TBNA Samples
TBNA specimens were collected on clean glass slides. The histo-
logic core of the tissue was gently removed from the slide and placed
in a formalin solution. The cytologic material was smeared and sub-
sequently stained with May–Gru¨nwald Giemsa, Papanicolaou, and
Ziehl–Neelsen stains.
Pathologists blinded to the patient’s clinical and radiologic de-
tails performed the categorization of TBNA samples. The presence
of material consistent with the architecture of lymph nodes (histo-
logic samples) or the presence of a preponderance of lymphocytes
(cytologic samples) defined the adequacy of TBNA. A diagnostic
sample, histologic or cytologic, contained nonnecrotizing epitheli-
oid granulomas in the absence of identifiable foreign-body reactions
or positive stains for acid-fast bacilli and fungi.17,22,23
Statistical Analysis
Patients were compared for aspirate status (positive or negative)
with the use of the Mann–Whitney test for continuous variables
and the c2 test or the Fisher test as appropriate for categoric or nom-
inal variables. Associations between aspirates status and predictor
variables are reported as odds ratio (OR) with 95% confidence inter-
val (CI) and were evaluated with logistic regression model. Only
significant variables in univariate analysis (.2 level) or those deemed
clinically important were included in the multivariate model. Anal-
yses were performed with Statistica forWindows Software (StatSoft
Inc, Tulsa, Okla) and with the STATA software package (Stata Cor-
poration, College Station, Tex).
Results
During the study period, sarcoidosis was diagnosed in 53 of
61 patients who met the inclusion criteria. In the remaining 8
cases, other causes were responsible for the clinical and ra-
diologic findings (4 cases of lymphoproliferative disorders,
3 cases of mycobacterial infection, and 1 case of pneumoco-
niosis).
The final diagnosis was established on the basis of the re-
sults of the bronchoscopic sampling procedures in 50 of 61
cases (sarcoidosis in 47 patients and mycobacterial infection
in 3 patients), on the results of mediastinoscopy in 6 cases
(sarcoidosis in 2 patients and lymphoproliferative disorders
in 4 patients), and on the evaluation of current and follow-
up clinicoradiologic data in 5 cases (sarcoidosis in 4 patients
and pneumoconiosis in 1 patient).
Most patients with sarcoidosis in this series were initially
seenwith a variable combination of nonspecific constitutional
manifestations, respiratory symptoms, erythema nodosum,
and arthralgias. In a few cases, the possibility of sarcoidosisil 2008
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TSwas raised with respect to a symptom-free patient on the basis
of results of imaging studies performed for unrelated reasons
(chest radiography in the diagnostic workup preceding
surgery).
The 53 sarcoidosis patients were all white, had a mean 6
SD age of 44.7 6 12.7 years, and had a male/female ratio of
0.7. In 47 of 53 (89%), the definitive diagnosis was obtained
with the help of bronchoscopy procedures, whereas in 6 cases
it was achieved by either mediastinoscopy (n5 2) or clinicor-
adiologic follow-up (n 5 4). With respect to the broncho-
scopic procedures, the results of TBNA (overall 79%, stage
I 82%, stage II 75%) exceeded those of TBLB (overall
55%, stage I 41%, stage II 79%), although the best diagnostic
yield was obtained by combining the two methods (overall
89%, stage I 88%, stage II 90%). In 18 of 53 cases, the diag-
nosis of sarcoidosis was established exclusively by TBNA
(34% increase in diagnostic rate), whereas TBLB was the
only means of diagnosis in 5 of 53 cases (9% increase in di-
agnostic rate).
Table 1 shows the patient-based analysis of TBNA results
in the 53 patients with sarcoidosis. TBNA allowed material
representative of lymph node tissue to be obtained in 50 of
53 cases (94%). Nonnecrotizing epithelioid cell granulomas
were observed in TBNA samples in 42 of 53 cases (79%),
without differences between stages I (27/33, 82%) and II
(15/20, 75%).
The mean6 SD size of sampled lymph nodes was 1.856
0.43 cm. The diagnostic yield was significantly higher in pa-
tients who had two lymph nodes sampled relative to those
with only one sampled (25/27, 92.5%, vs 17/26, 65%, respec-
tively, P 5 .01).
Table 2 illustrates the results of the 80 TBNA procedures
performed on all the patients included according to the lymph
node station sampled. Sampled lymph nodes were located in
the following stations of the American Thoracic Society clas-
sification scheme19: subcarinal (n 5 41), right paratracheal
(n 5 30), right hilar (n 5 8), and left paratracheal (n 5 1).
Histologic tissue was obtained from 48 of 80 sampled lymph
nodes, whereas cytologic material was retrieved from 80 of
80 nodes. The percentages of both adequate and diagnostic
cytologic TBNA samples exceeded the percentages of histo-
logic ones (87.5% and 70%, respectively, vs 36% and 22.5%,
respectively).
Minor, self-resolving bleeding at the puncture site was the
only TBNA-associated complication observed.
Sampling of two lymph node stations versus one was the
only variable significantly associated with the likelihood of
a positive needle aspirate or biopsy sample (OR 0.15, 95%
CI 0.02–0.79, P 5 .02) at univariate analysis (Figure 1),
and it was confirmed as an independent predictor of signifi-
cance at multivariate analysis (OR 0.12, 95% CI 0.02–0.70,
P 5 .01; Figure 2). There was a trend toward statistical sig-
nificance when analyzing the impact of the operator perform-
ing the TBNA and the likelihood of a positive needle aspirateThe Journal of Thorat both univariate (OR 0.29, 95% CI 0.07–1.16, P5 .08) and
multivariate (OR 0.22, 95% CI 0.04–1.04, P 5 .057) analy-
ses. Because a TBNA cytologic sample representative of the
lymph node tissue was obtained in almost all cases (50/53,
94%), the adequacy of cytologic samples was not included
in the analysis. No correlation was seen between the likeli-
hood of a positive needle aspiration or biopsy sample and
patient age and sex, sarcoidosis stage, size and location of
sampled nodes, number of needle passes of sampled nodes,
or adequacy of histologic TBNA samples.
Discussion
This study of a large prospective series of patients with sar-
coidosis who underwent TBNA suggests that the method
has excellent diagnostic yield when hilar or mediastinal
lymph node enlargement is present, regardless of stage.
This observation, previously described by Wang and col-
leagues11 in a smaller series, is of particular importance be-
cause it contradicts earlier studies that reported a far lower
yield for TBNA predominantly in stage II,12-15 leading
some authors to hypothesize that stage II sarcoidosis lymph
nodes could have a lower density of granulomas than in stage
I.15,26 Several limitations of previous studies, such as retro-
spective design,14,15 exclusive acceptance of histologic
TBNA samples as diagnostic criteria,12,13 and lack of CT
guidance to map lymph node areas to be sampled,13 may
have contributed to the unsatisfactory yield reported with
TBNA in stage II sarcoidosis.
In our study, sampling of two lymph node stations versus
one was significantly associated with the likelihood of a pos-
itive needle aspirate or biopsy sample, and it was shown to be
an independent predictor of significance in the multivariate
model (Figures 1 and 2). A diagnosis of sarcoidosis was ob-
tained in 92.5% of patients who had two nodes sampled, as
compared with 65% who had only one, regardless of stage.
We therefore recommend sampling more than one nodal sta-
tion in patients with suspected sarcoidosis whenever possi-
ble. It would be important to assess in future studies,
however, whether the use of ROSE could help to reduce
the number of biopsy sites in patients with a strong clinical
likelihood of sarcoidosis10 In light of the excellent yield of
cytologic material in sarcoidosis.16,22,23,24-26 ROSE might
in fact obviate the need for further diagnostic sampling by
showing nonnecrotizing epithelioid granulomas.27,28
TABLE 1. Patient-based analysis of transbronchial needle
aspiration results
Sample type Adequate samples Diagnostic samples
Histologic plus
cytologic
50/53 (94%) 42/53 (79%)
Cytologic 50/53 (94%) 42/53 (79%)
Histologic 27/53 (51%) 16/53 (30%)acic and Cardiovascular Surgery c Volume 135, Number 4 839
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lymph node station







Procedures (No.) 80 41 30 1 8
Diagnostic samples (No.)
Histologic plus cytologic 58/80 (72.5%) 30/41 (73%) 23/30 (77%) 0/1 (0%) 5/8 (62.5%)
Cytologic 56/80 (70%) 29/41 (71%) 22/28 (78.5%) 0/1 (0%) 5/8 (62.5%)
Histologic 18/80 (22.5%) 12/41 (29%) 4/28 (14%) 0/1 (0%) 2/6 (33%)
Adequate samples
Cytologic 70/80 (87.5%) 36/41 (88%) 27/30 (90%) 0/1 (0%) 7/8 (87.5%)
Histologic 29/80 (36%) 17/41 (41%) 8/30 (27%) 0/1 (0%) 4/8 (50%)We also noted a correlation, although not of statistical sig-
nificance, between the operator and the TBNA yield at both
univariate and multivariate analyses (Figures 1 and 2). Al-
though both of the bronchoscopists involved in the study
have long-term experience with TBNA,8,15,16 which is the
first-step technique for diagnosing hilar and mediastinal
lymphadenopathy at our institution, their diagnostic yields
were different (86% vs 65%). This is not surprising, because
TBNA is probably the most operator-dependent broncho-
scopic sampling procedure,6 and its results have been shown
to change in time with experience and practice.29
When examining the results of TBNA according to the
American Thoracic Society lymph node station, the best suc-
cess rates were obtained in our series from aspirates or biop-
sies performed in the right paratracheal (77%) and subcarinal
(73%) areas. Interestingly, enlarged lymph nodes in at least
one of these two stations were found by CT scan in the
vast majority of cases (50/53, 94%), allowing us to perform
most TBNAs in those areas (71/80, 89%). It is likely that
this high prevalence of enlarged right paratracheal and sub-
carinal nodes contributed to the high yield that we achieved,
because sampling from those areas has consistently been as-
sociated with the best TBNA results in the settings of both
neoplastic and nonneoplastic disorders.6,8,15,16,20,21 This
may also explain in part why we obtained good results
even though we used a blind technique. On the other hand,
recent studies suggest that guiding TBNA with real-time
imaging devices such as ultrasounds might further improve
the diagnostic yield of TBNA [24-26].
We obtained rates of successful lymph node sampling of
94% in the patient-based analysis (Table 1) and 72.5% in
the procedure-based analysis (Table 2), even though we lim-
ited the number of needle passes for each sampled node to
three at the most. The ability to achieve a diagnosis with
a low number of needle passes (#3), which is critical to bron-
choscopy time management, has already been demonstrated
in studies evaluating TBNA in the mediastinal staging of
lung cancer.7 Recently, Diacon and associates30 showed
that three transbronchial needle passes are appropriate
when only a tissue diagnosis is sought and when alternative
sites or sampling modalities are available. Limiting TBNA
performance time yet preserving its yield is of particular
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Figure 1. Univariate analysis showing
odds ratios of predictor variables of trans-
bronchial needle aspiration (TBNA) yield.840 The Journal of Thoracic and Cardiovascular Surgery c April 2008
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Figure 2. Multivariate analysis show-
ing odds ratios of predictor variables
of transbronchial needle aspiration
(TBNA) yield.G
TSimportance in sarcoidosis, because a combined approach in-
cluding TBNA and TBLB increases the diagnostic success in
this setting,12-16 and it is warranted in the absence of ROSE.
This observation is confirmed in our study, in which the com-
bination of TBLB and TBNA was associated with a higher
diagnostic yield than was TBNA alone (89% vs 79%). Re-
markably, however, our study demonstrates that TBNA is su-
perior to TBLB for patients with sarcoidosis seen with hilar
or mediastinal lymphadenopathy (yields of 79% vs 55%, re-
spectively), especially in stage I of the disease (82% vs 41%,
respectively).15,16
Unlike repeated observations in the mediastinal staging of
lung cancer, we did not find a correlation between the node
size in its short-axis diameter and TBNA yield. This observa-
tion likely reflects the uniformly large lymph nodes (mean6
SD 1.856 0.43 cm) in our patients, a feature common to sar-
coidosis series.24
In this study, the diagnostic contribution of cytologic
TBNA material was higher than that of histologic samples
in both the patient-based (79% vs 30%) and the procedure-
based analyses (70% vs 22.5%), a finding that contrasts
with reports from other investigators and our own previous
experience. Morales and coworkers12 and Wang and col-
leagues11 were able to obtain diagnostic tissue in 51% and
90% of patients with sarcoidosis, respectively, with the 19-
gauge histology needle. In a previous series of 32 patients
with stage I sarcoidosis, we obtained adequate and diagnostic
histologic TBNA specimens in 64% and 61% of procedures,
respectively.16 With the growing experience of pathologists
in the interpretation of TBNA cytologic material in the set-
ting of lung cancer, we have increased the use of 22-gauge
cytology needles in the last few years, with satisfactory re-
sults. This may have impaired our ability to use large-bore
histology needles, leading to inappropriate specimen re-
trieval or recovery of inadequate samples. On the other
hand, a growing body of literature suggests that the demon-The Journal of Thorstration of nonnecrotizing epithelioid granulomas on cyto-
logic material is feasible and reliable.16,22,23,24-26,28 In this
particular study, TBNA cytology showed nonnecrotizing
granulomas in every single patient who had a positive
TBNA histologic study result (16/16 patients). We believe,
however, that an attempt to obtain a histologic core tissue
with a 19-gauge needle should always be made in patients
with suspected sarcoidosis, because histologic evaluation is
more reliable in the exclusion of alternative diagnosis, such
as lymphoproliferative disorders and tuberculosis.16,22
Some limitations to this study need to be assessed to
place it into proper context. Although an alternative diagno-
sis was demonstrated in 13% of patients (8/61), the pretest
probability of our study population was high, and TBNA
was used in most cases to confirm a strong clinical expecta-
tion of sarcoidosis. Our results therefore may not be readily
reproducible in an unselected group of patients with hilar or
mediastinal lymphadenopathy. We performed most of our
procedures in lymph node stations (right paratracheal and
subcarinal) that are known to yield the best results with
standard TBNA. We are well aware that this choice of bi-
opsy site might create a bias, but we considered the selec-
tion of enlarged nodes from areas that are known to be
associated with unsatisfactory results with standard TBNA
to be ethically unjustifiable. On the other hand, we believe
it is important for the community of thoracic surgeons and
interventional pulmonologists to appreciate that more than
90% of patients with suspected sarcoidosis may have
lymphadenopathy in areas that are likely to be successfully
sampled with standard TBNA.
In conclusion, standard TBNA allows successful lymph
node sampling in most patients with sarcoidosis with hilar
or mediastinal lymph node enlargement, and it is associated
with a high diagnostic yield regardless of the sarcoidosis
stage. Sampling of more than one lymph node station, when-
ever possible, is recommended to increase the likelihood ofacic and Cardiovascular Surgery c Volume 135, Number 4 841
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TSa positive diagnosis. Mediastinoscopy should be reserved for
patients with negative TBNA findings.
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